Jean-Christophe Tellier, UCB CEO (Jasper Jacobs/Belga/Sipa USA/Sipa via AP Images)

January 4, 2024 03:29 PM EST

UCB departs industry trade group BIO, following Pfizer's exit late last year

Zachary Brennan

Senior Editor

Brussels-based biopharma company UCB confirmed Thursday that it decided not to renew its membership in the industry group BIO in 2024, the second high-profile exit …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

UCB departs industry trade group BIO, following Pfizer's exit late last year

Zachary Brennan

Senior Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

At Jefferies, all that manufacturers want to talk about is GLP-1s

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

UCB de­parts in­dus­try trade group BIO, fol­low­ing Pfiz­er's ex­it late last year

Zachary Brennan

Senior Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

UCB departs industry trade group BIO, following Pfizer's exit late last year

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

At Jefferies, all that manufacturers want to talk about is GLP-1s

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?